Arthritis & Rheumatology
Fecha de publicación: 5 de diciembre de 2020
DOI: https://doi.org/10.1002/art.41596
Autores: Ted R. Mikuls, Sindhu R. Johnson, Liana Fraenkel, Reuben J. Arasaratnam, Lindsey R. Baden, Bonnie L. Bermas, Winn Chatham, Stanley Cohen, Karen Costenbader, Ellen M. Gravallese, Andre C. Kalil, Michael E. Weinblatt, Kevin Winthrop, Amy S. Mudano, Amy Turner, Kenneth G. Saag
Objective: To provide guidance to rheumatology providers on the management of adult rheumatic disease in the context of the coronavirus disease 2019 (COVID‐19) pandemic.
Methods: A task force, including 10 rheumatologists and 4 infectious disease specialists from North America, was convened. Clinical questions were collated, and an evidence report was rapidly generated and disseminated. Questions and drafted statements were reviewed and assessed using a modified Delphi process. This included asynchronous anonymous voting by email and webinars with the entire panel. Task force members voted on agreement with draft statements using a 1–9‐point numerical scoring system, and consensus was determined to be low, moderate, or high based on the dispersion of votes. For approval, median votes were required to meet predefined levels of agreement (median values of 7–9, 4–6, and 1–3 defined as agreement, uncertainty, or disagreement, respectively) with either moderate or high levels of consensus.
Leer más
Comentarios
Para dejar un comentario antes debes iniciar sesión:
¿No tienes una cuenta?
Regístrate a través de éste enlace.